PanoramicaGraficoNotizieSchermataTrader

UC BON.CERT. BAYN/  DE000HD22EL7  /

gettex Zertifikate
07/11/2024  13:45:09 Var.- Denaro14:58:14 Lettera- Sottostante Prezzo di esercizio Expiration date Tipo di opzione
24.530EUR - 24.630
Quantità in denaro: 20,000		 -
Quantità in lettera: -		 BAYER AG NA O.N. - - 31/12/2024 Call
TeleTrader 08/11 Europe closes lower as focus remains on rate calls, political news
TeleTrader 16/08 Bayer jumps 10% after Roundup court win
GlobeNewswire 02/08 Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire 11/07 AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire 25/06 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
GlobeNewswire 30/05 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire 30/05 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 28/05 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
TeleTrader 14/05 Bayer's sales in Q1 at €13.7 billion, down 4.3%
GlobeNewswire 02/05 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire 18/04 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire 16/04 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire 11/04 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire 09/04 AskBio Names Mansuo Shannon Chief Scientific Officer
GlobeNewswire 25/03 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire 14/03 Bayer and Aignostics to collaborate on next generation precision oncology
GlobeNewswire 06/03 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
TeleTrader 05/03 Bayer's Q4 sales at €11.9 billion
GlobeNewswire 04/03 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
TeleTrader 04/03 Earnings preview: Bayer, Broadcom among those in calendar
GlobeNewswire 15/02 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire 13/02 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire 13/02 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
TeleTrader 29/01 Bayer down over 5% after latest $2.25B Roundup ruling